- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00863551
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
January 28, 2016 updated by: Allergan
This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms.
Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured.
Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Glendale, California, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 75 years (OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, 65-75 years of age without evidence of memory impairment
- Subject has overactive bladder symptoms but otherwise healthy
- Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit)
- Weight within normal range
- Ability to follow study instructions and likely to complete all required visits
Exclusion Criteria:
- Residual urine within bladder greater than 4 ounces
- Moderate or severe memory impairment
- Bleeding disorder
- Blood-thinning agents
- Concurrent overactive bladder medication
- Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), galantamine or similar drugs for dementia
- Chronic kidney failure
- Abdominal bypass surgery for obesity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Trospium Chloride Extended Release, 60 mg
|
Extended release, 60 mg, oral daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5
Time Frame: Day 10, Hour 5
|
Cerebral spinal fluid levels of Trospium at day 10, hour 5. Cerebral spinal fluid was collected from each patient.
|
Day 10, Hour 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose
Time Frame: Day 10
|
The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall).
It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition.
The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn.
The total score ranges from 0 (no memory) to 36 (best memory).
|
Day 10
|
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function Delayed Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) at Day 10 Post-Dose
Time Frame: Day 10
|
The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall).
It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial.
The delayed recall score provides a measure of the patient's recent memory.
The total score ranges from 0 (no memory) to 12 (best memory).
|
Day 10
|
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Total Score at Day 10 Post-Dose
Time Frame: Day 10
|
The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall).
It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial.
The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn.
The total score ranges from 0 (no memory) to 12 (best memory).
Due to technical problems associated with the administration of the test, the results were invalid.
|
Day 10
|
Percentage of Study Subjects With No Clinically Significant Effect on Neurocognitive Function as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall Score at Day 10 Post-Dose
Time Frame: Day 10
|
The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall).
It consists of 3 learning trials: free recall, delayed recall, and a yes/no delayed recognition trial.
The delayed recall score, derived from the delayed recall trial, provides a measure of the patient's recent memory.
The total score ranges from 0 (no memory) to 12 (best memory).
Due to technical problems associated with the administration of the test, the results were invalid.
|
Day 10
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
August 1, 2009
Study Registration Dates
First Submitted
March 16, 2009
First Submitted That Met QC Criteria
March 16, 2009
First Posted (ESTIMATE)
March 18, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
February 26, 2016
Last Update Submitted That Met QC Criteria
January 28, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Trospium chloride
Other Study ID Numbers
- MA-SXR-09-001
- SMART Trial (OTHER: Allergan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Trospium Chloride
-
University of North Carolina, Chapel HillAmerican Urogynecologic SocietyCompletedUrinary Bladder, Overactive | Cognitive Function | Mental CompetencyUnited States
-
Endo PharmaceuticalsAlkermes, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
AllerganCompleted
-
AllerganCompletedObesity | Overactive Bladder | IncontinenceUnited States
-
Karuna TherapeuticsTerminated
-
Karuna TherapeuticsCompletedSchizophrenia | Schizophrenia; PsychosisUnited States, Ukraine
-
Karuna TherapeuticsEnrolling by invitationSchizophreniaUnited States, Bulgaria, Serbia
-
Karuna TherapeuticsCompletedSchizophreniaUnited States, Ukraine
-
Karuna TherapeuticsActive, not recruiting
-
Karuna TherapeuticsRecruitingSchizophreniaUnited States, Bulgaria, Serbia